BACKGROUND: Active surveillance (AS) is an appropriate management strategy for men with low-risk prostate cancer. Most protocols recommend repeated prostate biopsy every 12-24 months. The purpose of this paper is to describe histological inflammation patterns in men on AS who underwent serial prostate biopsy for disease monitoring. METHODS: We reviewed records of men on AS from January 1999 through February 2011 who had a diagnostic plus X1 repeat transrectal ultrasound-guided biopsies performed at our institution. The type and degree of inflammatory infiltrate were grossly reviewed and scored for each patient's biopsy by a single pathologist. Relationship of inflammation severity and number of serial biopsies was assessed using a repeated measures mixed model. Unpaired t-test and w 2 -square analysis assessed variance in degree of inflammation and location of inflammation relative to cancer grade progression defined as Gleason sum increase. RESULTS: Fifty-six men met study inclusion criteria. Mean age was 62.1 (6.5) years, 71% were stage cT1c, 79% had a PSA level o10 ng ml À 1 , and 98% had diagnostic Gleason sum p6. A small, statistically significant increase in maximum chronic inflammation (CI) scores with greater number of repeat biopsies was observed. CI scores were not associated with number of biopsies based on upgrade status. The main limitation to our study is our small sample size. Potential unmeasured confounders, such as unreported antibiotic use or symptomatic prostatitis, may have also affected our findings. CONCLUSIONS: In this pilot study of 56 men on AS for localized prostate cancer, degree of chronic histological inflammation increased with greater number of prostate biopsies, but was not associated with subsequent risk of grade progression.
INTRODUCTION
One in six men are diagnosed with prostate cancer in the US, 1 with nearly three quarters classified as low-risk (stage T1c or less) disease. 2 Active surveillance (AS) is an appropriate management strategy for many of these men, which is increasingly used in contemporary practice. Institutional monitoring protocols recommend repeat transrectal ultrasound (TRUS)-guided prostate biopsy every 12-24 months, as alternative, noninvasive clinical parameters such as PSA kinetics are not proven to predict disease progression. [3] [4] [5] While the risks of infection and minor complications following biopsy are well-established, 6, 7 few studies have examined the chronic or late clinical/histological outcomes of serial biopsy in AS populations. 8 As chronic inflammation (CI) and/or infection results in an estimated 20% of all adult cancers including lung, liver, stomach and large intestine, 9 many studies have evaluated the association between inflammation and prostate cancer. [10] [11] [12] [13] [14] [15] Histological inflammation within the prostate is thought to result from local infection, trauma (such as prostate biopsy), high circulating levels of testosterone and dietary or environmental pollutants. 9, 16 Several studies suggest key inflammation signaling pathways have a critical role in the etiology and progression of prostate cancer. 9, 17, 18 Long-term histological changes and associated clinical impact that result from repeated prostate biopsy are largely unknown and have not been previously described.
Our objectives were to describe histological inflammation patterns in prostate glands of men who underwent serial TRUS-guided prostate biopsy. We also explore the association between CI and prostate cancer grade progression in patients on AS at our institution.
MATERIALS AND METHODS

Study population
After obtaining institutional review board approval and patient consent, we retrospectively reviewed records from men enrolled under our AS protocol January 1999 through February 2011 at the University of California San Francisco (UCSF). The majority of patients met specific AS selection criteria, including diagnostic Gleason score (GS)p6 with no pattern 4 or 5, PSA o10 ng ml À 1 , clinical stagepT2a and p33% biopsy cores cancer positive. We included those patients who had diagnostic plus 1 or more repeat TRUS-guided sextant biopsies at UCSF, with at least 10 cores taken. All biopsy tissue slides were originally treated by hematoxylin and eosin stain staining and had undergone routine pathology evaluation by a UCSF genitourinary pathologist. GS and core location of tumor within each biopsy were noted. After clinical use, biopsy slides are available for institutional review board-approved research purposes with patient consent. Slides were not available for all patients eligible for this analysis due to insufficient amounts of tumor or previous use by competing research studies. A single pathologist (MB) reviewed available tissue slides under light microscopy and assigned inflammation scores based on the study measure.
Study measure
Histologic prostate inflammation is defined by the National Institutes of Health as a distinct category and referred to as asymptomatic category IV prostatitis. 19 We used this consensus and validated definition to describe inflammation on biopsy specimens as has been used by other groups in the literature. 10, 12, 13, 20, 21 Acute inflammation (AI) consists mostly of neutrophils, whereas CI is reflected primarily by lymphocytes with variable numbers of plasma cells, macrophages and eosinophils. The degrees of both AI and CI were scored per individual core on a 4-point scale based on average cell density and extent of tissue involvement as 0 (none), 1 (mild or o15 cells per nest), 2 (moderate or 415 cells per nest), 3 (severe or extensive multifocal sheets or confluent masses with tissue destruction present). 21 Individual cores were also categorized as to whether inflammatory infiltrate and cancer were present within the same core.
Data analysis
Baseline demographic and disease features, as well as inflammation scores were described using means and frequencies. For each biopsy, we computed 'average' AI and CI scores based on the mean of scores from all cores. Each biopsy was also assigned 'maximum' AI and CI scores, each reflecting the highest score among cores taken. Scores were plotted for each patient's successive biopsies (diagnostic through fifth) to identify possible patterns between degree of inflammation and biopsy sequence. Scores were also examined for correlations with and plotted by individual patients' total number of biopsies.
Inflammation scores across consecutive biopsies were charted based on high (above median) or low (below median) baseline score to look for variation between patients and adjust for differences in baseline inflammation. Clinical factors that may be associated with inflammation were identified a priori: patient age, prostate volume, diagnostic PSA and National Comprehensive Cancer Network clinical risk at diagnosis. We reviewed the presence/absence of urologist-diagnosed BPH, defined as pharmacological or surgical treatment for lower urinary tract symptoms and/or TRUS proven prostate size 440 ml. We further reviewed records for documentation of symptomatic prostatitis, as well as use of chronic nonsteroidal anti-inflammatory (NSAID) medication. Change in scores across consecutive biopsies was then assessed using a repeated measures mixed model, adjusting for these factors. As our AS protocol recommends TRUSguided prostate biopsy every 12-24 months, inter-biopsy timing was not adjusted for. PSA velocity (PSAV) for individual patients was computed and Pearson's R was used to assess the relationship of PSAV with total biopsy number, as well as maximum CI score of last biopsy.
A secondary analysis of CI and relationship to cancer upgrade also was performed. Differences in average and maximum CI scores based on grade progression (an increase in either primary or secondary Gleason pattern after diagnostic biopsy) were assessed using a t-test. We also described the location of CI relative to cancer core in each man's last upgraded biopsy. Types of active treatment, if any, also were reported. A P-value o0.05 was considered significant. SAS 9.1 for Windows (SAS Institute, Cary, NC, USA) was used for analysis.
RESULTS
Of the 604 men enrolled under our AS protocol during the study period, 133 had diagnostic biopsies performed at UCSF. Of these, 79 men had complete sets of slides available for rereview. Fifty-six men who underwent two or more biopsies and met inclusion criteria formed the study cohort. A total of 191 biopsies and 1327 cores were reviewed and inflammation was scored. Patients who met inclusion criteria did not differ from those excluded based on demographics or disease features (race, PSA, PSAV, clinical T-stage, GS, clinical risk group, number of biopsies and months of followup) with the exception of age. Men included were younger (mean age 62 years) compared with men excluded (mean age 66 years), Po0.01 (data not shown).
Demographic and baseline clinical data are summarized in Table 1 . Forty (71%) were clinical stage T1c, 44 (79%) had PSA p10 ng ml À 1 and 55 (98%) had diagnostic GSp6. No patients were identified as having symptomatic prostatitis within 6 months preceding entry into the AS program. Thirty-one (55%) had known BPH and 17 (30%) were on long-term nonsteroid anti-inflammatory therapy (that is, aspirin, ibuprofen) at study entry. Mean follow-up was 64.1 ( ± 26.5) months. Twenty men (36%) had a total of two biopsies, 10 (18%) had three biopsies, 14 (25%) had four biopsies and 12 (21%) had five or more biopsies. Biopsies were performed at mean time intervals of 19 ( ± 13) months (median 16.5, range 2-71, months), guided by surveillance protocol.
Average AI was 0 or very mild with overall score of 0.14 (±0.20). Maximum AI scores were distributed as 52% with no (score ¼ 0), 43% with mild (1), 4% with moderate (2) and 1% with severe (3) inflammation. Maximum AI by total number of biopsies and biopsy sequence are shown in Figure 1 . Maximum AI score remained between 0 and 1 regardless of total biopsy exposure.
Similarly, the overall average CI score was low at 0.46 ( ± 0.46). Maximum CI score was the most pronounced as 19% had no, 46% had mild, 28% had moderate and 7% had severe inflammation. Maximum scores by total number of biopsies and biopsy sequence are shown in Figure 2 . Maximum CI score at diagnosis was between 1 and 2 for those with one to four biopsies and below 1 for those with five biopsies (N ¼ 12).
Adjusted average and maximum AI and CI scores are presented in Figure 3 . After adjusting for age, prostate volume, clinical risk and BPH, there was no statistically significant change in AI across successive biopsies. Conversely, average CI scores slightly increased with increasing number of biopsies (nonsignificant, P ¼ 0.08) and maximum CI scores demonstrated a small, though significant, increase with each successive biopsy (P ¼ 0.04). Median PSAV during study period was 0.06 (interquartile range À 0.31, 0.49). No correlation was seen between PSAV and total biopsy number (Pearson's R ¼ À 0.02, P ¼ 0.87).
Nineteen (34%) men experienced a GS upgrade from p6 at diagnosis, with 11 (56%) of these occurring at second biopsy. Of those with grade progression, 14 (74%) increased to 3 þ 4, two (4%) to 4 þ 3, two (4%) to 4 þ 4 and one to 5 þ 4. The majority of men (82%) had CI on diagnostic biopsy and these men had a slightly higher rate of grade progression compared with those Table 2 . CI was located within the same core in 5 (26%) of those with grade progression and 10 (27%) of those without progression (P ¼ 0.26). Treatment-free survival was 56% at 5 years with 25 men eventually undergoing definitive treatment. Of these, treatment was triggered by grade progression in 13 (52%) patients, volume progression in 3 (12%), PSA progression in 2 (8%) and patient choice in 7 (28%). Radical prostatectomy was performed in 22 (88%) and 3 (12%) had radiation therapy. Of the patients with biopsy upgrade, 10 (53%) underwent radical prostatectomy, 2 (10%) underwent radiation therapy and 7 (37%) elected no treatment to date.
DISCUSSION
There is a paucity of literature on long-term adverse events and effects associated with serial TRUS-guided biopsy, which is the cornerstone of most AS protocols. Specifically, the impact of repeated biopsy on histological inflammation patterns (classified as asymptomatic category IV prostatitis by the National Institutes of Health 19 ) is largely unknown. As multiple forms of physical and chemical trauma, as well as foreign microbes are known to promote inflammation within the prostate, 9 we hypothesized that repeated physical insult from the biopsy needle or possible inoculation of bacteria would produce unique inflammation patterns in patients who undergo sequential or annual biopsy as part of an AS management strategy. This paper describes AI and CI patterns in 56 patients who underwent serial prostate biopsy (mean interval 19±12.9 months) as part of UCSF's AS protocol. After controlling for age, prostate volume, diagnostic PSA, National Comprehensive Cancer Network clinical risk, as well as BPH and NSAID use, repeated biopsy was associated with very small increases in CI and no significant change in AI severity. Maximum CI largely remained between 1 (mild) and 2 (moderate) in patients who underwent two or more repeat biopsies. Similarly, average CI scores remained low after successive biopsy. Figure 4 depicts light microscopy images of varying degrees of histological AI and CI.
Several studies have investigated the role histological inflammation has in risk and progression of prostate cancer. MacLennan et al 10 examined prostate tissue of 177 patients older than 45 years, who underwent prostate needle biopsy for PSA44 ng ml À 1 and/or abnormal digital rectal exam, noting histological abnormalities and degrees of CI within individual cores. Repeat biopsies were performed in half of the cohort over a 5-year period and 20% of those with baseline CI experienced a new cancer diagnosis, while five patients experienced an upgrade in GS. The majority of men with incident cancer had history of other histological abnormalities such as post-atrophic hyperplasia, proliferative inflammatory atrophy, high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation, which have been identified as precursors to adenocarcinoma. 13 The authors questioned whether men with baseline CI should be considered at higher risk for prostate cancer and thus be managed similarly to those with precancerous lesions such as atypical small acinar proliferation. Similarly, this paper inquired whether men with low-grade disease accompanied by CI should be managed more aggressively. Contrary to MacLennan's findings, several studies have found completely opposite 11, 14, 20, 22 or benign disease. 12, 13 We explored the association between biopsy upgrade and CI in our study population and observed no difference in the degree of CI between men who did and did not upgrade. In this small study, the biopsy progression rate was 34% over an average of 64.1 (±26.5) months follow-up, which is similar to that of other surveillance studies previously published. 23, 24 As other groups have described, our findings support that inflammation is often multifocal and not necessarily present within the same location as cancer, even in those who experience an upgrade in GS. 10, 25 In our cohort, men with biopsy progression experienced a similar rate of CI found within cancer core as men without progression (26% and 27%, respectively). Importantly, in the 19 men who upgraded, 10 (53%) had no CI present within any core of the upgraded biopsy.
Chronic inflammatory infiltrate is largely comprised of lymphocytes, which are responsible for complex molecular signaling that is thought to promote cancer progression in mouse and human models. 26 Tumor-associated inflammation is a well-documented phenomenon in prostate cancer, especially in advanced disease. Inflammation is elicited and even accelerated after therapy-induced death of primary tumor tissue (that is, castration), and the ensuing signaling milieu is thought to have a significant role in the emergence of androgenindependent prostate cancer. 26 Activation of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) either due to pro-inflammatory stimuli or a mutation in the upstream signaling cascade, such as IkB kinase, is observed in lymphoid cancers and many solid tumors. 27 More recently it has been shown that prostate cancer-associated lymphocytes activate these unique signaling cascades, resulting in the production of cytokines that stimulate proliferation and enhance survival of malignant carcinoma cells. 26, 28, 29 While we did not observe a statistically significant difference in the degree of inflammation based on upgrade status in this small study, this does not negate the important role local inflammation has in pathogenesis of prostate cancer. Future studies that assess the degree of upregulation of specific chemokines and/or associated receptors or other molecules that indicate induction of inflammatory pathways must be considered.
While we had a limited sample size, this is the first study to address whether repeated TRUS-biopsy contributes to inflammation in men undergoing AS for localized prostate cancer. AS is increasingly accepted as an appropriate management strategy for men with low-risk, localized disease and the long-term impact of biopsy monitoring remains largely unassessed. Other strengths of the study include use of a single pathologist to record inflammation scores, which were based on a welldefined, systematic grading system. Importantly, while considered the 'gold standard' for cancer detection, prostate biopsy is imperfect, as up to 38% of cancers are missed. 30 Early cancer upgrades (that is, at second or third biopsy) often represent initial undersampling of the prostate during diagnostic biopsy. 31 Thus, because of this inherent sampling error, large areas of inflammation may have been missed, potentially skewing our results. Other key limitations to our study include small sample size, largely due to lack of slide availability (as many patients underwent diagnostic biopsy at an outside institution), which may contribute to an unmeasurable patient selection bias. Those included were younger compared with those excluded (62 vs 66 years) but otherwise had similar disease characteristics and thus largely reflect the population of men who undergo AS at our institution. We also attempted to control for other potential confounders such as BPH and chronic NSAID use; however, we could not account for severity or dosage. While no patient had symptomatic prostatitis upon AS entry, one patient had known acute prostatitis seven months before initiating AS and five patients developed acute prostatitis after a period of AS and multiple biopsies. Although all were treated with antibiotics and/or NSAID therapy before subsequent biopsy, untreated or persistent prostatitis is an important potential confounder in our study population. Other influences of histologic inflammation including recent antibiotic use (other than for prostatitis), circulating levels of androgens or dietary factors, were not accounted for due to the retrospective nature of this study. In addition, we did not account for the presence of other prostatic lesions such as high-grade prostate intraepithelial neoplasia, post-atrophic hyperplasia or proliferative inflammatory atrophy. 9, 13, 32 Unfortunately, histological prostate inflammation is an imperfect marker as it has a variety of etiologies and is often found incidentally in tissue specimens of men with known BPH or who are of advanced age. 13 Furthermore, it has been linked to progression of BPH 21, 33, 34 and worsening of lower urinary tract symptoms, 35 as well as elevated PSA. 12 Additionally, the relationship between PSA kinetics and histological inflammation severity is well-described; inflammation is associated with higher circulating PSA levels, a trigger for repeat biopsy, 36, 37 which may have created a selection bias within this cohort. In our analysis, we found no statistical correlation between PSAV and number of TRUS-guided biopsies. CONCLUSION Serial prostate biopsy was associated with small increases in chronic histologic inflammation in this study of 56 men on AS. Furthermore, severity of CI was not associated with cancer upgrade in patients with low-risk disease. Despite the study's limitations and small size, we provide a relatively novel finding of a potential long-term outcome of repeated prostate needle biopsy. We further add insight into the role of histological inflammation and infiltrate severity on tumor upgrading in men with low-risk prostate cancer. Future study of serial biopsies and inflammation is warranted, with large, longitudinal populations and centralized pathology review to confirm these findings.
